The 8-hour Buprenorphine Training - PART 1
This is PART 1 of the 8-hour MOUD Training - ALL MEDICAL PROFESSIONALS and STUDENTS ARE WELCOME TO PARTICIPATE!
(PART 2 will be available to you once it has been verified that PART 1 has been completed in its entirety of 4.25-hours)
NOTE: This training has a starting time of 8:00 AM Eastern Time.
Please check your time zone for start time and download the Zoom app prior to training. https://zoom.us/ent?zcid=2582
The 1st half of the training is a 4.25-hour live webcast and 1A AOA CME is offered and sponsored by the AOAAM for Part 1 only!
Part 2 Instructions will be provided ONLY to participants who complete Part 1 in its entirety. This will be sent via email and will also become available on the AOAAM learner software once your certificate of CME has been claimed. Please note that CME for Part 2 is sponsored by AAAP and their CME credits are jointly accredited by ACCME, ACPE, and ANCC.
You must be both online viewing and listening to the presentation. Participation in the interactive polling questions is also required in order for the AOAAM to verify attendance. PHONE ONLY PARTICIPATION DOES NOT QUALIFY FOR CREDIT.
This training will count towards the DEA’s 8-hour training requirement when applying for or renewing your DEA license.
Section 1262 of the Consolidated Appropriations Act, 2023 (also known as Omnibus bill), removes the federal requirement for practitioners to submit a Notice of Intent and obtain a waiver to your DEA license to prescribe schedule III-V medications, approved by the FDA for the treatment of opioid use disorder (OUD).
The Consolidated Appropriations Act of 2023 enacted a new one-time, eight-hour training requirement for all Drug Enforcement Administration (DEA)-registered practitioners on the treatment and management of patients with opioid or other substance use disorders.
Beginning on June 27, 2023, practitioners will be required to check a box on their online DEA registration form, affirming that they have completed the new training requirement.
Funding for this initiative was made possible (in part) by cooperative agreement nos. 1H79TI086770 and 1H79TI085588 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
This course has been reviewed and is acceptable for 4.25 credits of AOA Category 1A by the AOA CCME. It has also been reviewed and is acceptable for 4.25 Prescribed credit(s) by the American Academy of Family Physicians.
Physicians should claim only the credit commensurate with the extent of their participation in the activity. AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed credit, not as Category 1.
William Morrone, DO, MPH, DABAM, FACOFP & DAAPM, is Medical Director at Recovery Pathways, investigator in a naloxone distribution for Mid-Michigan, Medical Director of 35th Circuit Shiawassee County Drug Court, Associate Professor of Family and Community Medicine, Michigan State University for 18 years and was Program Director of Family Medicine at Synergy Medical Education Alliance and liaison in the Dept of Psychiatry. He is triple board certified by the American Board of Addiction Medicine, American College of Osteopathic Family Practitioners and the American Academy of Pain Management. Dr. Morrone was a Ruth Fox faculty for the 42nd ASAM 2011 Medical-Scientific Conference Washington DC and is an active addiction educator and social advocate in pain management. Dr. Morrone is Director of the Saginaw Chippewa Tribal Court & commissioner on the Governor’s Impaired Driving Commission 2017-2019; he is also Assistant Prof Johns Hopkins School of Nursing.